Summary
Firebrick Pharma Limited (FRE) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Firebrick Pharma Limited ever had a stock split?
Firebrick Pharma Limited Profile
| Biotechnology Industry | Healthcare Sector | Dr. Peter Laurence Molloy BSc, FAICD, MBA CEO | CXA Exchange | - ISIN |
| Australia Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Firebrick Pharma Limited is an innovative biopharmaceutical company focused on the development and commercialization of novel therapeutics. Founded in 2012 and headquartered in Melbourne, Australia, the company specializes in addressing one of the most common health complaints globally—the common cold. By leveraging cutting-edge research and development, Firebrick Pharma aims to reduce the impact of the common cold on individuals' daily lives and the broader public health system. Its strategic approach to product development, centered on the antimicrobial spray Nasodine, positions the company as a potential leader in non-prescription solutions against common viral respiratory infections.
Products and Services
Firebrick Pharma's product portfolio is anchored by its flagship product:
- Nasodine Nasal Spray: A broad-spectrum antimicrobial spray designed for the treatment of the common cold. This innovative product represents the culmination of years of research into safe and effective methods to mitigate the severity and duration of cold symptoms. By targeting the nasal cavity, where most cold viruses first take hold, Nasodine offers a direct approach to combating viral infections at their source.
